COVID-19感染免疫检查点抑制剂患者的结局

TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021 Pub Date : 1900-01-01 DOI:10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4833

S. Minkove, J. Sun, X. Cui, D. Cooper, P. Eichacker, P. Torabi-Parizi

{"title":"COVID-19感染免疫检查点抑制剂患者的结局","authors":"S. Minkove, J. Sun, X. Cui, D. Cooper, P. Eichacker, P. Torabi-Parizi","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4833","DOIUrl":null,"url":null,"abstract":"ationale H mmune checkpoint inhibitor CI whether prior ICI treatment worsens or improves outcomes with this virus. To address this issue, we performed a systematic review of studies of cancer patients with COVID-19 that ret","PeriodicalId":297107,"journal":{"name":"TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021","volume":"349 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Patients on Immune Checkpoint Inhibitors Infected with COVID-19\",\"authors\":\"S. Minkove, J. Sun, X. Cui, D. Cooper, P. Eichacker, P. Torabi-Parizi\",\"doi\":\"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ationale H mmune checkpoint inhibitor CI whether prior ICI treatment worsens or improves outcomes with this virus. To address this issue, we performed a systematic review of studies of cancer patients with COVID-19 that ret\",\"PeriodicalId\":297107,\"journal\":{\"name\":\"TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021\",\"volume\":\"349 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

既往的免疫检查点抑制剂CI治疗是否会恶化或改善该病毒的预后。为了解决这个问题，我们对COVID-19癌症患者的研究进行了系统回顾

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Outcomes of Patients on Immune Checkpoint Inhibitors Infected with COVID-19

ationale H mmune checkpoint inhibitor CI whether prior ICI treatment worsens or improves outcomes with this virus. To address this issue, we performed a systematic review of studies of cancer patients with COVID-19 that ret

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

TP138. TP138 THORACIC ONCOLOGY: BASIC SCIENCE ADVANCES 2021

自引率

0.00%

发文量